Afficher la notice abrégée

Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCOURTINARD, Coralie
dc.contributor.authorGOURGOU, Sophie
dc.contributor.authorJACOT, William
dc.contributor.authorCARTON, Matthieu
dc.contributor.authorGUERIN, Olivier
dc.contributor.authorVACHER, Laure
dc.contributor.authorBERTAUT, Aurelie
dc.contributor.authorLE DELEY, Marie-Cecile
dc.contributor.authorPEROL, David
dc.contributor.authorMARINO, Patricia
dc.contributor.authorLEVY, Christelle
dc.contributor.authorUWER, Lionel
dc.contributor.authorPERROCHEAU, Genevieve
dc.contributor.authorSCHIAPPA, Renaud
dc.contributor.authorBACHELOT, Florence
dc.contributor.authorPARENT, Damien
dc.contributor.authorBRETON, Mathias
dc.contributor.authorPETIT, Thierry
dc.contributor.authorFILLERON, Thomas
dc.contributor.authorLOEB, Agnes
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMATHOULIN-PELISSIER, Simone
dc.contributor.authorROBAIN, Mathieu
dc.contributor.authorDELALOGE, Suzette
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.date.accessioned2023-04-17T12:49:12Z
dc.date.available2023-04-17T12:49:12Z
dc.date.issued2023-03-08
dc.identifier.issn1741-7015en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/173020
dc.description.abstractEnBACKGROUND: Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence remains scarce regarding the degree of association between PFS and OS. Our study aimed to describe the individual-level association between real-world PFS (rwPFS) and OS according to first-line treatment in female patients with mBC managed in real-world setting for each BC subtype (defined by status for both hormone-receptor [HR] expression and HER2 protein expression/gene amplification). METHODS: We extracted data from the ESME mBC database (NCT03275311) which gathers deidentified data from consecutive patients managed in 18 French Comprehensive Cancer Centers. Adult women diagnosed with mBC between 2008 and 2017 were included. Endpoints (PFS, OS) were described using the Kaplan-Meier method. Individual-level associations between rwPFS and OS were estimated using the Spearman's correlation coefficient. Analyses were conducted by tumor subtype. RESULTS: 20,033 women were eligible. Median age was 60.0 years. Median follow-up duration was 62.3 months. Median rwPFS ranged from 6.0 months (95% CI 5.8-6.2) for HR-/HER2 - subtype to 13.3 months (36% CI 12.7-14.3) for HR + /HER2 + subtype. Correlation coefficients were highly variable across subtypes and first-line (L1) treatments. Among patients with HR - /HER2 - mBC, correlation coefficients ranged from 0.73 to 0.81, suggesting a strong rwPFS/OS association. For HR + /HER2 + mBC patients, the individual-level associations were weak to strong with coefficients ranging from 0.33 to 0.43 for monotherapy and from 0.67 to 0.78 for combined therapies. CONCLUSIONS: Our study provides comprehensive information on individual-level association between rwPFS and OS for L1 treatments in mBC women managed in real-life practice. Our results could be used as a basis for future research dedicated to surrogate endpoint candidates.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enReal-word data
dc.subject.enBreast cancer
dc.subject.enOverall survival
dc.subject.enProgression-free survival
dc.subject.enAssociation
dc.subject.enSurrogacy
dc.title.enAssociation between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
dc.title.alternativeBMC Meden_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1186/s12916-023-02754-5en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36882736en_US
bordeaux.journalBMC Medicineen_US
bordeaux.volume21en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04071677
hal.version1
hal.date.transferred2023-04-17T12:49:16Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMC%20Medicine&rft.date=2023-03-08&rft.volume=21&rft.issue=1&rft.eissn=1741-7015&rft.issn=1741-7015&rft.au=COURTINARD,%20Coralie&GOURGOU,%20Sophie&JACOT,%20William&CARTON,%20Matthieu&GUERIN,%20Olivier&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_BMCM_2023_Courtinard.pdf
Taille:
1.891Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée